

Debbie Crumrine¹, Peter M. Elias¹ and Mao-Qiang Man¹

¹Dermatology Service, Veterans Affairs Medical Center, and Department of Dermatology, University of California San Francisco, San Francisco, California, USA

E-mail: mqman@hotmail.com

²These authors contributed equally to this work.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at <http://www.nature.com/jid>

REFERENCES

- Aberg KM, Man MQ, Gallo RL *et al.* (2008) Co-Regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. *J Invest Dermatol* 128:917–25
- Bourguignon LY, Wong G, Xia W *et al.* (2013) Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction. *J Dermatol Sci* 72:32–44
- Choi EH, Man MQ, Xu P *et al.* (2007) Stratum corneum acidification is impaired in moderately aged human and murine skin. *J Invest Dermatol* 127:2847–56
- Elavarasan J, Velusamy P, Ganesan T *et al.* (2012) Hesperidin-mediated expression of Nrf2 and upregulation of antioxidant status in senescent rat heart. *J Pharm Pharmacol* 64:1472–82
- Ghadially R, Brown BE, Sequeira-Martin SM *et al.* (1995) The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. *J Clin Invest* 95:2281–90
- Gounder SS, Kannan S, Devadoss D *et al.* (2012) Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training. *PLoS One* 7:e45697
- Hou M, Man M, Man W *et al.* (2012) Topical hesperidin improves epidermal permeability barrier function and epidermal differentiation in normal murine skin. *Exp Dermatol* 21:337–40
- Ilic D, Bollinger JM, Gelb M *et al.* (2014) sPLA2 and the epidermal barrier. *Biochim Biophys Acta* 1841:416–21
- Man G, Mauro TM, Kim PL *et al.* (2014) Topical hesperidin prevents glucocorticoid-induced abnormalities in epidermal barrier function in murine skin. *Exp Dermatol* 23:645–51
- Mauro T, Holleran WM, Grayson S *et al.* (1998) Barrier recovery is impeded at neutral pH, independent of ionic effects: implications for extracellular lipid processing. *Arch Dermatol Res* 290:215–22
- Pełal A, Drózdź P, Biesaga M *et al.* (2011) Evaluation of the antioxidant properties of fruit and flavoured black teas. *Eur J Nutr* 50:681–8
- Rodriguez-Martin M, Martin-Ezquerro G, Man MQ *et al.* (2011) Expression of epidermal CAMP changes in parallel with permeability barrier status. *J Invest Dermatol* 131:2263–70
- Schäfer M, Farwanah H, Willrodt AH *et al.* (2012) Nrf2 links epidermal barrier function with antioxidant defense. *EMBO Mol Med* 4:364–79
- Thomas AC, Tattersall D, Norgett EE *et al.* (2009) Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in harlequin ichthyosis. *Am J Pathol* 174:970–8
- Ye J, Garg A, Calhoun C *et al.* (2002) Alterations in cytokine regulation in aged epidermis: implications for permeability barrier homeostasis and inflammation. I. IL-1 gene family. *Exp Dermatol* 11:209–16

A Spontaneous *KRT16* Mutation in a Dog Breed: A Model for Human Focal Non-Epidermolytic Palmoplantar Keratoderma (FNEPPK)

Journal of Investigative Dermatology (2015) 135, 1187–1190; doi:10.1038/jid.2014.526; published online 15 January 2015

TO THE EDITOR

The keratin 16 gene (*KRT16*) encodes an intermediate filament protein mainly expressed in palmoplantar epidermis. In humans, mutations in *KRT16* are responsible for pachyonychia congenita and focal non-epidermolytic palmoplantar keratoderma (FNEPPK; Smith *et al.*, 2000; McLean and Moore, 2011). One of the main symptoms is a painful thickening of the palms and soles. To understand molecular mechanisms involved in this keratoderma, Krt16 mutant mouse models have been developed, but only one reproduces fully the palmoplantar phenotype (Lessard and Coulombe, 2012). In this study, we present a spontaneous canine model of FNEPPK inherited as an autosomal recessive disorder in the Dogue de Bordeaux breed. Because of its population

structure, which features genetic isolates, the purebred dog model has recently proven its utility in understanding the molecular mechanisms of hereditary cornification disorders, notably in humans and dog Autosomal Recessive Congenital Ichthyosis (Grall *et al.*, 2012).

We investigated a family of 130 dogs including 28 affected animals; no sex bias was observed among the 13 males and 15 females analyzed. The onset usually occurred between 10 weeks and 1 year of age. First described by Paradis (1992), affected dogs exhibit a painful thickening of the footpads with severe keratinous proliferations and fissures only at the ground contact locations similar to those observed in FNEPPK patients (Figure 1). Cracks predispose the dogs to secondary

infections, leading to lameness, causing the dog to be reluctant to walk. Nails did not seem to be affected, as reported in some human FNEPPK patients and in Krt16-null mice models (Shamsher *et al.*, 1995; Smith *et al.*, 2000; Liao *et al.*, 2007; Lessard and Coulombe, 2012). Similarly, no other cutaneous sign such as oral leukoplakia, cysts, or follicular keratosis was reported. This is concordant with our results of quantitative reverse transcription PCR of messengerRNA from unaffected dog biopsies, showing strong and specific expression of *KRT16* in the footpad, nose, and keratinocytes but not in body skin, oral mucosa, or other organs (data not shown).

Histopathological examinations of footpad biopsies revealed thick hyperkeratotic digital epidermis that was roughened by marked conical papillae with a prominent “church




Figure 1. Clinical phenotype and histopathological findings of footpad keratoderma in the Dogue de Bordeaux. (a) Footpad of a 3-year-old unaffected dog. (b) Footpad of an 8-year old and (c) a 1-year old affected dog. (d–h) Hematoxylin and eosin (HE) staining of footpad biopsies. (d) Unaffected dog (scale bar = 100 μm). (e–h) Footpad of an 8-year-old affected dog. (e) Thick hyperkeratotic digital epidermis (scale bar = 100 μm); (f) Thin compact column of parakeratotic cells (scale bar = 100 μm); (g) Higher magnification reveals a thinner or even absent granular layer (scale bar = 50 μm). (h) Irregular prominent granular layer, dyskeratosis, and light keratotic plugging at the bottom of two epidermal valleys (scale bar = 100 μm).




Figure 2. Immunoperoxidase and immunofluorescence staining of unaffected and affected footpad biopsies with alpha-K1, alpha-K6, and alpha-K16. Keratin 1 (a, d, g, j) and keratin 6 (b, e, h, k) have an expected diffuse and suprabasal expression in the epidermis in both in unaffected and affected dogs. (c, i) For keratin 16, a diffuse and suprabasal expression is observed in the epidermis in unaffected dogs (i, l), whereas keratin 16 is weakly or not detected in the epidermis of affected dogs. Scale bar = 100 μm.

spire” appearance (Figure 1e). On the top of this, there is a thin compact column of parakeratotic cells with

absent or decreased underlying granular layer and cytoplasmic vacuolization of superficial corneocytes at their base

(Figure 1f and g). Outside the conical papillae, the epidermis exhibited a well-developed granular layer and compact

orthohyperkeratosis. Between the conical papillae, small valleys were observed that presented dyskeratosis, an irregular and prominent granular layer, and light to moderate keratotic plugging (Figure 1h). No epidermolytic changes were noticed. Chronic superficial perivascular dermal infiltrate was sometimes observed.

Immunohistochemistry and immunofluorescence staining were performed on FFPE skin biopsies from four affected and four unaffected dogs. The Ki67 proliferation index showed that, as expected, keratinocytes in affected footpads were not proliferating. Expression of keratin 1, 6, and 16 was investigated in normal footpad biopsies (Figure 2). As previously described (Bowden *et al.*, 2009), keratin 1, 6, and 16 are co-expressed in the suprabasal layer of the footpad epidermis, with K16 located in the center of the rete ridges. No differences were observed in the expression of K1 and K6 between cases and controls. However, immunostaining revealed an abnormal distribution of K16 in affected samples: although K16 expression was diffuse and suprabasal all over the thickness of the epithelial layer of control dogs, its expression was not detected in affected samples (Figure 2). In affected dogs, discrete aggregates of K16 could be observed in the cornified layer in footpads not in contact with the ground (Supplementary Figure S1a online).

In parallel, we performed a genetic linkage study on the Dogue de Bordeaux family using 14 affected and 54 unaffected dogs genotyped on the canine 173,000 SNP array (Illumina, San Diego, CA). We identified a 20 Mb locus corresponding to the dog type I keratin cluster. We carried out mutation screening on several keratins in 14 affected dogs and 16 controls and identified a complex mutation in *KRT16* corresponding to an insertion/deletion (indel) of four nucleotides and a separate 1 bp deletion 15 nucleotides downstream in exon 6 (Supplementary Figure S2 online). This complex indel results in an insertion of 1 bp in affected dogs and introduces a frameshift changing the sequence of 10 amino acids and creating a premature stop codon (p.Glu392*) in the open reading frame of the gene.

This stop codon located in the 2B domain leads to the loss of the last 85 amino acids of K16, including the helix termination motif (Supplementary Figure S2 online). This sequence is the most highly conserved motif in keratins involved in the end-to-end interactions in keratin assembly. Mutations removing or changing the sequence of the tail domain leading to the production of truncated or mutated keratins have already been described for keratin 10 in humans and dog patients (Credille *et al.*, 2005; Müller *et al.*, 2006; Gutierrez *et al.*, 2013) and for *KRT16* in human patients (Smith *et al.*, 2000). It has been suggested that the disruption of the filament assembly could potentially lead to an abnormal distribution of the protein and the creation of aggregates (Smith *et al.*, 2000; Müller *et al.*, 2006) similar to what we observed in Dogues de Bordeaux (Supplementary Figure S1a online).

To confirm that this mutation is causative and specific to the Dogue de Bordeaux, we sequenced a set of 334 Dogues de Bordeaux with known clinical status. All affected dogs were homozygous for the complex mutation, and all unaffected dogs were either homozygous for the wild-type alleles or heterozygous (245/306 and 61/306, respectively). Furthermore, the mutated allele was never detected in a panel of 344 unaffected dogs from 80 different breeds.

Interestingly, heterozygous dogs do not present symptoms that is similar to the situation observed in *Krt16*-null mice (Lessard and Coulombe, 2012). This feature is also observed in other mutated keratin recessive disorders, such as the epidermolytic palmoplantar keratoderma *Krt9*^{-/-} mouse model (Fu *et al.*, 2014), *KRT10* mutations in humans and dog epidermolytic hyperkeratosis (Credille *et al.*, 2005; Müller *et al.*, 2006; Gutierrez *et al.*, 2013), or *KRT14* mutations in epidermolysis bullosa simplex patients (Titeux *et al.*, 2011). These examples of rare recessive forms show that, in the carrier population, the healthy allele could compensate for the loss of expression of the mutated allele, suggesting a mechanism different from haploinsufficiency usually reported in dominant inheritance.

qRT-PCR analysis of *KRT16* mRNA expression demonstrated a strong reduction (80%) in affected footpads (Supplementary Figure S1b online). This observation is concordant with the absence of the K16 protein as observed by immunostaining (Figure 2). As suggested by other studies, loss of one keratin alters the expression patterns of other plantar keratins, notably in response to skin injury (DePianto and Coulombe, 2003; Lessard *et al.*, 2013). These keratins could form an atypical heterodimer between the partner of the mutated keratin (here, K6a), and other type I keratins, leading to the hyperproliferative phenotype (Müller *et al.*, 2006). In the Dogue de Bordeaux keratoderma, *KRT14* mRNA levels and K6 distribution, as observed by immunostaining, were not significantly altered and other keratins are under investigation.

Spontaneous models such as dog breeds that fully reproduce human diseases prove useful in understanding the genetics and the physiopathology of these diseases and can lead to the development of efficient new therapies.

ETHICS STATEMENT

The work with dog samples was approved by the CNRS ethical board, France (35-238-13), for UMR 6290. Blood and tissue biopsy samples and pedigrees from dogs were collected by a network of veterinarians through the CaniDNA biobank developed by CNRS in 2000 (<http://dog-genetics.genouest.org>). The dog owners consented to the use of data for research purposes anonymously.

CONFLICT OF INTEREST

The authors CK, CDdC, AT, and GQ are employees of Antagene, a private company selling diagnostic tests in dogs. The remaining authors state no conflict of interest.

ACKNOWLEDGMENTS

We are grateful to the Brittany Region (France; PhD funding for JP), the European FP7 LUPA project (GA-201370), the Centre National de la Recherche Scientifique (CNRS), and the French Society of the Dogue de Bordeaux breed (SADB) with the French Kennel Club SCC (Société Centrale Canine) for funding and to the veterinarians, breeders, and to dog owners who provided samples, pedigree, and clinical data; we especially thank B. Hedan, C. De Brito, M. Heuze, R. Lavoue, X. Langon, T. Bord, P. Autret, and E. Voisin for clinical data as well as

Anne-Sophie Lequarré for her invaluable help. Finally, we warmly thank S. Cure for English corrections and her kind availability.

Jocelyn Plassais^{1,2}, Eric Guaguère³,
Laetitia Lagoutte^{1,2},
Anne-Sophie Guillory^{1,2},
Caroline Dufaure de Citres⁴,
Frédérique Degorce-Rubiales⁵,
Maxence Delverdière⁶,
Amaury Vaysse^{1,2,7,8}, Pascale Quignon^{1,2},
Céline Bleuar⁶, Christophe Hitte^{1,2},
Alain Fautrel⁹, Cecile Kaerle⁴,
Pascale Bellaud¹⁰, Emmanuel Bensignor¹¹,
Guillaume Queney⁴,
Emmanuelle Bourrat¹²,
Anne Thomas^{4,13} and
Catherine André^{1,2,13}

¹CNRS, UMR 6290, Institut de Génétique et Développement de Rennes, Rennes, France; ²Université Rennes 1, UEB, Biosit, Faculté de Médecine, Rennes, France; ³Clinique Vétérinaire Saint Bernard, Lomme, France; ⁴Antagene, Animal Genetics Laboratory, La Tour de Salvagny, France; ⁵Laboratoire d'Anatomie Pathologique Vétérinaire du Sud-Ouest LAPVSO, Toulouse, France; ⁶Service d'Anatomie Pathologique, Ecole Vétérinaire de Toulouse, Toulouse, France; ⁷INSERM, UMR 946, Genetic Variation and Human Diseases Unit, Paris, France; ⁸Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France; ⁹INSERM, UMR 991, Université de Rennes 1, Biosit Biogenouest, Rennes, France; ¹⁰Université de Rennes1, Plateforme H2P2, Biosit Biogenouest, service d'anatomie pathologiques, Rennes,

France; ¹¹Clinique Vétérinaire de la Boulais, Cesson-Sévigné, France and ¹²Département de Dermatologie, Hôpital Saint-Louis, Paris, France
E-mail: catherine.andre@univ-rennes1.fr
¹³These authors contributed equally to this work.

SUPPLEMENTARY MATERIAL

Supplementary material is linked to the online version of the paper at <http://www.nature.com/jid>

REFERENCES

- Bowden PE, Henderson H, Reilly JD (2009) Defining the complex epithelia that comprise the canine claw with molecular markers of differentiation. *Vet Dermatol* 20:347–59
- Credille KM, Barnhart KF, Minor JS *et al.* (2005) Mild recessive epidermolytic hyperkeratosis associated with a novel keratin 10 donor splice-site mutation in a family of Norfolk terrier dogs. *Br J Dermatol* 153:51–8
- DePianto D, Coulombe PA (2003) Intermediate filaments and tissue repair. *Exp Cell Res* 301:68–76
- Fu DJ, Thomson C, Lunny DP *et al.* (2014) Keratin 9 is required for the structural integrity and terminal differentiation of the palmoplantar epidermis. *J Invest Dermatol* 134:754–63
- Grall A, Guaguère E, Planchais S *et al.* (2012) PNPLA1 mutations cause autosomal recessive congenital ichthyosis in golden retriever dogs and humans. *Nat Genet* 44:140–7
- Gutierrez JA, Hannoush ZC, Vargas LG *et al.* (2013) A novel non-sense mutation in keratin 10 causes a familial case of recessive epidermolytic ichthyosis. *Mol Genet Genomic Med* 1:108–12

- Lessard JC, Coulombe PA (2012) Keratin 16-null mice develop palmoplantar keratoderma, a hallmark feature of pachyonychia congenita and related disorders. *J Invest Dermatol* 132: 1384–91
- Lessard JC, Piña-Paz S, Rotty JD *et al.* (2013) Keratin 16 regulates innate immunity in response to epidermal barrier breach. *Proc Natl Acad Sci USA* 110:19537–42
- Liao H, Sayers JM, Wilson NJ *et al.* (2007) A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. *J Dermatol Sci* 48:199–205
- McLean WHI, Moore CBT (2011) Keratin disorders: from gene to therapy. *Hum Mol Genet* 20:R189–97
- Müller FB, Huber M, Kinaciyan T *et al.* (2006) A human keratin 10 knockout causes recessive epidermolytic hyperkeratosis. *Hum Mol Genet* 15:1133–41
- Paradis M (1992) Footpad hyperkeratosis in a family of dogues de bordeaux. *Vet Dermatol* 3:75–8
- Shamsher MK, Navsaria HA, Stevens HP *et al.* (1995) Novel mutations in keratin 16 gene underlying focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families. *Hum Mol Genet* 4:1875–81
- Smith FJ, Fisher MP, Healy E *et al.* (2000) Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma. *Exp Dermatol* 9:170–7
- Titeux M, Décha A, Pironon N *et al.* (2011) A new case of keratin 14 functional knockout causes severe recessive EBS and questions the haploinsufficiency model of Naegeli-Franceschetti-Jadassohn syndrome. *J Invest Dermatol* 131:2131–3

More People Die from Thin Melanomas (≤ 1 mm) than from Thick Melanomas (> 4 mm) in Queensland, Australia

Journal of Investigative Dermatology (2015) 135, 1190–1193; doi:10.1038/jid.2014.452; published online 13 November 2014

TO THE EDITOR

Melanoma incidence has been rising steadily in fair-skinned populations around the world, with most of the increase due to greater numbers of thin lesions being diagnosed (Welch *et al.*, 2005; Coory *et al.*, 2006; Gimotty *et al.*, 2007). Melanoma mortality has also been rising, albeit less rapidly compared with incidence (Welch *et al.*,

2005; MacKie *et al.*, 2007). Survival from melanoma is strongly correlated with tumor thickness; patients with thin lesions (≤ 1 mm) have a 20-year survival approaching 96%, whereas thicker lesions confer substantially higher risks of premature mortality (Balch *et al.*, 2009; Green *et al.*, 2012). On the basis of these prognostic associations, there is a widespread perception that the

majority of deaths from melanoma result from thick lesions. However, data describing population distributions of lethal melanomas by thickness have been seldom reported (Criscione and Weinstock, 2010) and may have been biased by missing thickness data (Shaikh *et al.*, 2013). Such analyses are important for understanding where the burden of melanoma mortality lies and would serve to inform melanoma control strategies. We therefore performed an analysis of melanoma incidence and mortality in Queensland, Australia, the

Abbreviation: QCR, Queensland Cancer Registry

Accepted article preview online 20 October 2014; published online 13 November 2014